Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
September 17 2021 - 4:10PM
Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the
Company’s annual meeting of shareholders, on September 14, 2021, at
9:00 a.m. was convened and adjourned, without any business being
conducted, due to lack of the required quorum.
A quorum consists of a majority of the shares
entitled to vote. There were fewer than a majority of shares
entitled to vote present, either in person or by proxy at this
meeting. Approximately 45.6% were properly voted at the time of the
annual meeting. The annual meeting of shareholders therefore had no
quorum and the meeting was adjourned and will reconvene at 9:00
a.m. (Pacific Time) on Tuesday, October 5, 2021 to be held
virtually at www.virtualshareholdermeeting.com/ONVO2021 to allow
additional time for the Company’s shareholders to vote on the
proposals set forth in the Company’s definitive proxy statement
filed with the United States Securities and Exchange Commission
(the “SEC”) on August 5, 2021.
During the current adjournment, the Company
continues to solicit votes from its shareholders with respect to
the proposals set forth in the Company’s proxy statement. Only
shareholders of record, as of the record date, July 19, 2021, are
entitled to and are being requested to vote.
Important Information
This material may be deemed to be solicitation
material in respect of the Annual Meeting to be reconvened and held
on October 5, 2021. In connection with the Annual Meeting, the
Company filed a definitive proxy statement with the SEC on August
5, 2021. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE
URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy
statement was mailed to shareholders who are entitled to vote at
the Annual Meeting. No changes have been made in the proposals to
be voted on by stockholders at the Annual Meeting. The Company’s
proxy statement and any other materials filed by the Company with
the SEC can be obtained free of charge at the SEC's website at
sec.gov or the Company’s
website https://ir.organovo.com/financial-information/sec-filings.
About Organovo
Organovo is an early-stage biotechnology company
that is developing and utilizing highly customized 3D human tissues
as dynamic models of healthy and diseased human biology for drug
development. The company’s proprietary technology is being used to
build functional 3D human tissues that mimic key aspects of native
human tissue composition, architecture, function and
disease. Organovo’s advances include cell type-specific
compartments, prevalent intercellular tight junctions, and the
formation of microvascular structures. Management believes these
attributes can enable critical complex, multicellular disease
models that can be used to develop clinically effective drugs for
selected therapeutic areas.
Forward Looking Statements
Any statements contained in this press release
that do not describe historical facts constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. These risks and
uncertainties and other factors are identified and described in
more detail in the Company’s filings with the SEC, including
its Annual Report on Form 10-K filed with
the SEC on June 15, 2021. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United
States, the Company does not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
Investor Contact
Amato and Partners, LLCInvestor Relations
Counseladmin@amatoandpartners.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jul 2023 to Jul 2024